Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy

MT Newswires49minutes ago · Ratings

SKB BIO-B (06990.HK) established a market management service agreement with Kelong Jialin.

SKB BIO-B (06990.HK) announced that on February 12, 2025, the company entered into a market management service framework agreement with Corun Jiaxun, under which Corun Jiaxun and/or its affiliates will provide market management services to the company for the research and development of the recombinant epidermal growth factor receptor (EGFR) human-mouse chimeric monoclonal antibody (monoclonal antibody) Cetuximab N01 injection (formerly A140) (Datalay).

Gelonghui FinanceFeb 12 04:50 ET

SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting

MT NewswiresFeb 11 05:00 ET

[Hong Kong Stock Connect] Kelun-Botai Biopharmaceutical (06990) will announce the research results of its core products at the USA Clinical Oncology Society Cancer Conference.

Jinwu Financial News | Cerenbo Tai Biological (06990) announced that the company will present its antibody-drug conjugate (ADC) sac-TMT (formerly known as SKB264/MK-2870) targeting tumor-associated calcium signal transducer 2 (TROP2) at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium to be held from February 13 to 15, 2025. This will be for the treatment of patients with unresectable, locally advanced, or metastatic urothelial carcinoma (UC) who have previously received anticancer therapy or have experienced disease progression after treatment.

Jinwu Financial NewsFeb 10 19:55 ET

SKB BIO-B (06990.HK): The core product Alkanxatuzumab (SAC-TMT) will present research findings at the 2025 ASCO GU Cancer Symposium.

On February 11, Gelonghui reported that SKB BIO-B (06990.HK) announced it will present at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in San Francisco from February 13 to February 15, 2025, the findings of its antibody-drug conjugate (ADC) sac-tamtuzumab (formerly known as SKB264/MK-2870) for the monotherapy of inoperable cancer in patients who have previously received cancer therapies or have experienced disease progression after treatment.

Gelonghui FinanceFeb 10 18:42 ET

[Brokerage Focus] HAITONG INT'L: The development of Innovative Drugs requires a vibrant environment.

Jinwu Financial News | HAITONG INT'L stated that the development of Innovative Drugs requires a vibrant environment. Similar to all industries, whether the pharmaceutical industry can give birth to world-class companies depends first on the environment or ecosystem. On a Global scale, investing in disease spectra (oncology, metabolism, autoimmunity, central nervous system) and technological breakthroughs (such as IO bispecific antibodies, TCE bispecific antibodies) will be the main focus for the next five years. Innovative Drugs are labor and research-intensive industries, and their ecosystem is crucial because the emergence of Biopharma (biopharmaceutical companies) and MNC (multinational pharmaceutical companies) requires enterprises to promote research and development in various risk areas, with companies having world-class sales capabilities driving commercial success.

Jingwu Financial NewsFeb 10 03:26 ET